Quoin receives EMA orphan‑drug status for QRX003, paving way for rare‑skin‑disease trial
Quoin Pharmaceuticals said the European Medicines Agency awarded orphan‑drug designation to its candidate QRX003 for Peeling Skin Syndrome. The designation grants the drug up to ten years of exclusivity in the EU if it later obtains marketing approval. The company intends to begin its first formal clinical study for the condition before the end of 2026. QRX003 already holds orphan designations for Netherton Syndrome in the United States, Europe and Japan.
Why it matters
The EMA designation gives Quoin access to fee reductions, scientific advice and EU grant funding, which can lower development costs and improve the prospect of a market‑exclusive product. If the trial proceeds as planned, the exclusivity could enhance the company’s valuation in the niche rare‑dermatology market.
Key facts
- 1The European Medicines Agency granted orphan‑drug designation to QRX003 for Peeling Skin Syndrome. stocktitan.net
- 2The designation would provide up to ten years of market exclusivity in the EU after marketing approval. stocktitan.net
- 3Quoin plans to start the first formal clinical trial for Peeling Skin Syndrome before the end of 2026. stocktitan.net
- 4QRX003 also has orphan‑drug designations for Netherton Syndrome in the United States, Europe and Japan. stocktitan.net
- 5Quoin’s shares closed at $4.15 on the day of the announcement. rttnews.com
- 6An analyst set a price target of $14.00 for Quoin’s stock. tipranks.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.